STOCKS TELEGRAPH

Tag: Virpax Stock

  • Virpax Pharmaceuticals (VRPX) Stock Rises On Promising Study Results

    Virpax Pharmaceuticals (VRPX) Stock Rises On Promising Study Results

    Announcing positive results from a pilot study, shares of Virpax Pharmaceuticals, Inc. (NASDAQ: VRPX) have nearly doubled in value on the US stock charts today. As of the latest market assessment, VRPX stock has surged by 99.04%, reaching $2.30.

    Promising Study Results for Probudur

    Virpax Pharmaceuticals disclosed the results of a Swine Model pilot study for Probudur, their long-acting liposomal bupivacaine formulation designed for injection at wound sites to provide both immediate and extended pain relief. The purpose of the pharmacokinetics (PK) and safety investigation was to ascertain Probudur’s PK profile and pinpoint any negative effects on the pigs.

    In the study, Probudur was subcutaneously injected into four juvenile domestic pigs at a dose of 30 mg/kg. The formulation was well-tolerated by all pigs and demonstrated a long-term, slow-release profile. Histopathological analysis at the injection site also confirmed Probudur’s favorable tolerance in all subjects.

    Future Prospects and Strategic Developments

    The consistent positive results from the Probudur studies bolster Virpax’s belief in its potential to provide both immediate and sustained pain relief at wound sites. The company is negotiating additional funding from a new institutional investor and is conducting the remaining necessary studies. Virpax aims to file its Investigational New Drug (IND) application for Probudur by the end of the year.

    In authorized indications, Probudur is being developed to drastically reduce or completely remove the requirement for opioids after surgery. It functions as a local anesthetic by binding to sodium channels and preventing pain signals from reaching the brain.

    Pre-clinical studies have demonstrated Probudur’s efficacy in providing long-duration pain control for at least 96 hours, with a rat incisional model showing analgesia for up to five days and in vitro studies indicating a slow release of bupivacaine lasting up to six days.

    This week, Virpax also secured a $2.5 million loan from an institutional investor, facilitating the final payment of its litigation settlement. In conjunction with this financing, the Virpax Board of Directors underwent reorganization, reducing from eight to seven members. Four new board members were appointed by the institutional investor, and five members resigned.

  • Why Did VRPX Stock Fell 12% In Premarket Session?

    Why Did VRPX Stock Fell 12% In Premarket Session?

    The share price of Virpax Pharmaceuticals Inc. (VRPX) dropped to $4.54 as of the last check in premarket trade, a decline of -12.36%. Virpax shares rose 13.85% on Wednesday to close at $5.18. Volume of VRPX stock was 33.3 million, which was much higher than the average volume over the last three months of 358.59K. VRPX stock traded between $4.37 and $8.49 during the session. Profit taking is likely to be behind the decline in VRPX stock as in the past session, the stock price rose after the company provided progress updates on product candidates.

    What update VRPX has provided?

    Virpax develops proprietary technologies that optimize target drug delivery to develop non-addictive, branded pain management products. Its three patents for drug delivery platforms are the first thing VRPX plans to submit to the US Food and Drug Administration (“FDA”) for approval. Those candidates include Epoladerm, Probudur and Envelta.

    After Virpax’s initial public offering in February of 2021 and its review of its pipeline of product candidates, the company provided a progress report on those candidates yesterday.

    • After its IPO, VRPX wanted to become a clinical stage company as rapidly as possible, preserve its cash, and use grants for product development if needed.
    • VRPX has consistently progressed toward these goals to date.
    • In order to improve manufacturing capabilities and possible patent life, VRPX is refining some formulations.
    • The aim of VRPX in developing Epoladerm is to treat acute musculoskeletal pain and osteoarthritis with a metered-dose spray film formulation that contains diclofenac.
    • For the management of postoperative pain, Probudur is a liposomal bupivacaine formulation that is being developed by VRPX.
    • A formulation of molecular envelope enkephalin known as Envelta is being developed by VRPX as an intranasal treatment for chronic pain, including cancer-related pain.
    • As part of its evaluation of additional indications, VRPX is also evaluating its proprietary delivery technologies.
    • In addition, VRPX plans to initiate initial Investigational New Drug Application (“IND”)-enabling studies on several of its existing programs shortly.
    • Earlier this month, VRPX submitted MMS019, their intranasal molecular masking spray, to the US Food and Drug Administration (“FDA”).

    Virpax has announced that Envelta’s IND application has been enabled by clinical studies being conducted under a cooperative research and development agreement (CRADA). VRPX entered into an agreement with the National Center for Advancing Translational Sciences (NCATS) for chronic pain.

    VRPX further plans:

    Virpax (VRPX) plans to use the study to obtain INDs for two additional indications, cancer pain and Post-Traumatic Stress Disorder (PTSD). The NCATS has begun IND-enabling studies of Envelta to support the VRPX’s future application to the Food and Drug Administration (FDA) for clearance to begin its first-in-human clinical trials.